Pancreatic Cancer Archives - Page 3 of 43

A patient undergoes cancer-related surgery.

Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report

By

Randi Hernandez

February 5, 2020

ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.

The cancer field is not immune to the challenges of out-of-network and surprise billing.

General Oncology

The Unexpected Costs of Cancer Treatment: Out-of-Network Billing

By

Amber Dance, PhD

February 4, 2020

The cancer field is not immune to the challenges of out-of-network and surprise billing.

Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.

ASCO GI 2020

Addition of PEGPH20 to Frontline Chemotherapy Did Not Improve Clinical Outcomes in Pancreatic Cancer Subgroup

By

Susan Moench, PhD, PA-C

January 23, 2020

Pegvorhyaluronidase alfa is an enzyme that breaks down hyaluronan, thought to be a contributor to the structure of the tumor microenvironment in some pancreatic cancers.

$Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.$

ASCO GI 2020

Addition of Pegilodecakin to FOLFOX Did Not Improve OS in Metastatic Pancreatic Cancer

By

Susan Moench, PhD, PA-C

January 23, 2020

Promising results from an earlier-phase study of FOLFOX plus pegilodecakin in metastatic PDAC refractory to gemcitabine provided a rationale for this study.

Breast Cancer

No Link Found Between Hepatitis C Infection and Extrahepatic Cancers

By

Leah Lawrence

January 14, 2020

A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.

Pancreatic Cancer

Effects of Surgeon Volume, Nurse-to-Patient Ratio on Potential Complications With Pancreaticoduodenectomy

By

Vicki Moore, PhD

January 8, 2020

Although higher nurse-to-patient ratios ensure good outcomes for patients undergoing pancreaticoduodenectomy, PD-specific surgeon volume has a greater effect on risks of complications for these patients.